Per Ljungman focuses on Internal medicine, Transplantation, Immunology, Surgery and Hematopoietic stem cell transplantation. His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology and Oncology. His Transplantation research incorporates themes from Viral disease, Transplantation Conditioning, Aspergillosis and Letermovir.
His Immunology research includes elements of Disease and Intensive care medicine. His study in Surgery is interdisciplinary in nature, drawing from both Incidence, Cumulative incidence and Bone marrow. The various areas that Per Ljungman examines in his Hematopoietic stem cell transplantation study include Cord blood, Epstein–Barr virus infection, Hazard ratio, Cytotoxic T cell and Cidofovir.
His scientific interests lie mostly in Internal medicine, Transplantation, Immunology, Hematopoietic stem cell transplantation and Surgery. His Internal medicine research includes themes of Gastroenterology and Oncology. As a member of one scientific family, Per Ljungman mostly works in the field of Transplantation, focusing on Betaherpesvirinae and, on occasion, Congenital cytomegalovirus infection and Human cytomegalovirus.
The Immunology study combines topics in areas such as Disease and Virology. His research integrates issues of Human leukocyte antigen, Myeloid leukemia, Hazard ratio, Transplantation Conditioning and Acute leukemia in his study of Hematopoietic stem cell transplantation. In his study, Complication is inextricably linked to Bone marrow, which falls within the broad field of Surgery.
His primary scientific interests are in Internal medicine, Transplantation, Hematopoietic stem cell transplantation, Hematology and Gastroenterology. His study connects Oncology and Internal medicine. His work carried out in the field of Transplantation brings together such families of science as Hematopoietic cell, Young adult, Placebo, Lymphoma and Sick leave.
His studies deal with areas such as Leukemia, Immunology, Vaccination, Cell therapy and Graft-versus-host disease as well as Hematopoietic stem cell transplantation. His Immunology study frequently involves adjacent topics like Calcineurin. His Gastroenterology research integrates issues from Viremia, Serostatus, Viral load, Hazard ratio and Acute leukemia.
Internal medicine, Transplantation, Hematopoietic stem cell transplantation, Disease and Hematology are his primary areas of study. His Internal medicine research is multidisciplinary, relying on both Gastroenterology and Oncology. His Transplantation research is multidisciplinary, incorporating perspectives in Letermovir, Young adult, Placebo, Leukemia and Risk factor.
His Hematopoietic stem cell transplantation study integrates concerns from other disciplines, such as Myelofibrosis, Itraconazole and Fluconazole. His Disease study incorporates themes from Voriconazole, Posaconazole, Aspergillosis and Vaccination. His Hematology research focuses on Intensive care medicine and how it relates to Pandemic, Developing country, Coronavirus disease 2019 and Medical tourism.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Definitions of Cytomegalovirus Infection and Disease in Transplant Recipients
Per Ljungman;Paul Griffiths;Carlos Paya.
Clinical Infectious Diseases (2002)
2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
Lorry G. Rubin;Myron J. Levin;Per Ljungman;E. Graham Davies.
Clinical Infectious Diseases (2014)
Executive Summary: 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
Lorry G. Rubin;Myron J. Levin;Per Ljungman;Per Ljungman;E. Graham Davies.
Clinical Infectious Diseases (2014)
Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party.
Socié G;Henry-Amar M;Bacigalupo A;Hows J.
The New England Journal of Medicine (1993)
Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells.
K. Le Blanc;H. Samuelsson;B. Gustafsson;M. Remberger.
Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation
BB Bjorkstrand;P Ljungman;H Svensson;J Hermans.
How we treat cytomegalovirus in hematopoietic cell transplant recipients
Michael Boeckh;Per Ljungman.
A Randomized Trial Comparing Busulfan With Total Body Irradiation as Conditioning in Allogeneic Marrow Transplant Recipients With Leukemia: A Report From the Nordic Bone Marrow Transplantation Group
O Ringden;T Ruutu;M Remberger;J Nikoskelainen.
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
Francisco M Marty;Per Ljungman;Roy F Chemaly;Johan Maertens.
The New England Journal of Medicine (2017)
Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells.
Åsa Gustafsson;Victor Levitsky;Jie Zhi Zou;Teresa Frisan.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: